Jump to content

Samuel Broder

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jone Rohne Nester (talk | contribs) at 09:06, 22 July 2017 (adding reflist, cite, removing BLP unsourced tag). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Samuel Broder (1986).

Samuel Broder is an American oncologist and medical researcher. He was a co-developer of some of the first effective drugs for the treatment of AIDS and was Director of the National Cancer Institute (NCI) from 1989 to 1995.

During the first years of the AIDS epidemic, he co-developed zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), which were the first effective drugs licensed for the treatment of AIDS. In 1989, he was appointed by President Ronald Reagan to be Director of the NCI[1]. In this position he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). After leaving the NCI, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics. He is now Chief Medical Officer of Celera.

He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel Award.

References

  1. ^ "Intrexon Announces Retirement of Samuel Broder, M.D., Head of Health Sector". Intrexon InvestorRoom. Retrieved 22 July 2017.


Flag of United StatesScientist icon

This biographical article related to medicine in the United States is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Samuel_Broder&oldid=791758887"